适应性设计的疫苗临床试验的洞察力和益处:一个范围审查
Andrés Mauricio García-Sierra1,2, Luz Adriana Urbina Moreno1, Chloe Flanigan1,3
1EpiDriver, Ciudad de Panama 0843, Panama.
Translational and clinical pharmacology
|October 16, 2025
概括
适应性终点驱动的试验设计提高了疫苗研究的灵活性和效率. 本次审查强调了它们在预防性疫苗试验中的新兴实用性,尽管存在统计和监管方面的挑战.
科学领域:
- 临床试验 临床试验
- 疫苗学 疫苗学 疫苗学
- 公共卫生 公共卫生
背景情况:
- 疫苗对全球健康至关重要,由于人口增长和气候变化,疫苗面临传染病风险增加.
- 传统的疫苗评估随机对照试验 (RCT) 在时间,资源和道德上都有局限.
- 自适应端点驱动的设计提供灵活性,允许在试验期间进行协议修改.
研究的目的:
- 调查在预防性疫苗RCT中适应性终点驱动方法的实施情况.
- 确定在疫苗试验中使用的适应性策略,终点和支持工具.
- 评估这些适应性设计在疫苗研究中的好处和挑战.
主要方法:
- 根据PRISMA-P和乔安娜·布里格斯研究所的指导方针进行范围审查.
- 对MEDLINE,Embase和ClinicalTrials.gov进行I-III期疫苗RCT的系统搜索.
- 数据提取和偏差风险评估由多名审稿人进行,并进行描述性综合.
主要成果:
- 七项研究符合纳入标准,采用适应性方法,如中间分析和样本大小重新估计.
- 终点通过临床,实验室和监测数据确定,通常使用数字工具支持.
- 适应性方法提高了灵活性和效率,但存在统计和监管障碍.
结论:
- 适应性终端驱动设计在疫苗研究中显示出新兴的实用性,增强试验运行.
- 需要进一步开发终端工具和监管框架.
- 评估适应性设计对批准时间和公共卫生结果的影响至关重要.
更多相关视频
相关概念视频
Clinical Trials
10.1K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
10.1K
Clinical Trials: Overview
4.6K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.6K
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
404
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
404
Study Designs in Epidemiology
878
Epidemiological study designs are fundamental tools for investigating the distribution, determinants, and control of health conditions in populations. They help researchers understand the relationships between exposures and outcomes, and they broadly fall into two categories: "observational" and "experimental" studies.
Observational studies are those where the researcher does not intervene but rather observes natural variations. They include cross-sectional, cohort, and...
Observational studies are those where the researcher does not intervene but rather observes natural variations. They include cross-sectional, cohort, and...
878
Bioequivalence Experimental Study Designs: Repeated Measures, Cross-Over, Carry-Over, and Latin Square Designs
178
Body:Bioequivalence experimental study designs play a pivotal role in testing the effectiveness of various treatments. Key among these are the repeated measures, cross-over, carry-over, and Latin square designs. In the repeated measures design, each subject receives all treatments, allowing for temporal comparisons. This type of design is useful in reducing variability but requires careful planning to avoid bias.The cross-over design, an economical method, involves sequential administration of...
178
Bioequivalence studies: Biowaivers
220
Body:In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
220


